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Background: Osteosarcoma (OSA) represents the most common canine primary bone tumour. Despite several
pathways have been investigated so far, few molecules have been identified as prognostic tools or potential
therapeutic targets, and there is still the need to find out molecular pathways with specific influence over OSA
progression to facilitate earlier prognosis and treatment.
Aims of the present study were to evaluate the immunohistochemical pattern and levels of expression of a panel of
molecules (survivin, β-catenin, caspase 3 -inactive and active forms- and p53) involved in cell cycle and apoptosis
regulation in canine OSA samples, known to be of interest in the study also of human OSA, and to detect specific
relations among them and with histological tumour grade, disease free interval (DFI) and overall survival (OS).
Results: Nuclear β-catenin immunostaining was detected in normal osteoblasts adjacent to the tumour, and in
47% of the cases. Cytoplasmic and/or membranous immunostaining were also observed. Nuclear survivin and p53
positive cells were found in all cases. Moderate/high cytoplasmic β-catenin expression (≥10% positive cells) was
significantly associated with the development of metastasis (P = 0.014); moderate/high nuclear p53 expression
(≥10% positive cells) was significantly associated with moderate/high histological grade (P = 0.017) and shorter OS
(P = 0.049). Moderate/high nuclear survivin expression (≥15% positive cells) showed a tendency toward a longer OS
(P = 0,088).
Conclusions: The present results confirmed p53 as negative prognostic marker, while suggested survivin as a
potential positive prognostic indicator, rather than indicative of a poor prognosis. The detection of nuclear
β-catenin immunostaining in normal osteoblasts and the absent/low expression in most of the OSAs, suggested
that this pathway could not play a major role in oncogenic transformation of canine osteoblasts. Further studies are
needed to confirm these hypotheses.* Correspondence: ldellasalda@unite.it
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Osteosarcoma (OSA) represents the most common
primary bone tumour of both dog [1] and childhood/
adolescence [2]. Numerous histological and biological
features have been shown to be shared by canine and
human OSA to date [3-8], even if further studies are war-
ranted to define more precisely similarities and differences
of OSA in the two species, so as to really consider the dog
as a valuable spontaneous tumour model for human OSA.
Even if several pathways have been investigated in canine
OSA so far, few molecules have been identified as prognos-
tic tools or potential therapeutic targets [5,9-18]. Leading
on from this, there is still the need to investigate molecular
pathways with specific influence over canine OSA progres-
sion to facilitate earlier prognosis and treatment.
The goal of the present study was to evaluate a panel
of molecules involved in cell cycle and apoptosis regula-
tion in canine OSA samples, known to be of interest in
the study also of human OSA. Among these molecules,
of particular significance, the role of β-catenin, and the
related canonical Wnt pathway, has been largely investi-
gated in human OSA [19-26], but its exact role during
neoplastic transformation of osteoblast and OSA progres-
sion still remains a debated item. While several studies
indicated an important contribution of the activation of
the Wnt pathway in OSA development [19-25,27,28],
Cai et al. [26] have recently argued the opposite, suggesting
that the loss of Wnt pathway activity, which is required for
osteoblast differentiation, may contribute to OSA develop-
ment. Consequently, in contrast to other tumors, β-catenin
might not play an oncogenic role in OSA cells [26,29].
Survivin has been recently proposed as a prognostic
marker in human [30-35] and canine [36] OSA, but con-
trasting results have been observed concerning the rela-
tion between its subcellular localization and a favourable
or poor prognosis. One of the most important aspects of
the study of survivin expression in cancer is related to
its high cancer specificity and consequent potential role
as therapeutic target [37,38]. Survivin has been identified
as a target gene of the β-catenin pathway [39], and it
acts as a cell cycle regulator and apoptosis inhibitor,
even if different isoforms with different functions of the
molecule have been described [40].
Loss of p53 tumour suppressor gene functions have
been frequently reported in OSA, and mutated p53 has
been reported in both human and canine OSA [41]. An
interaction between p53 and β-catenin pathway has been
proposed to play a key role in osteoblast differentiation
and maintenance of bone tissue homeostasis [42].
Furthermore, activation of the Wnt/β-catenin signalling
has been shown to cause p53 accumulation [43].
The aims of the present study were to evaluate the
immunohistochemical pattern and levels of expression
of survivin, β-catenin, caspase 3 (inactive [procaspase 3]and active forms), and p53 in canine OSA samples, to
reveal specific relations among them and with histo-
logical tumour grade, disease free interval (DFI) and
overall survival (OS). The attempt is to contribute to a
better understanding of both the pathogenesis of canine
OSA and the role of the investigated molecules, in
particular establishing their role as prognostic biomarkers
and/or potential therapeutic targets. Interestingly, in this
study, the expression of nuclear survivin was mainly found
in less malignant OSA cases, and β-catenin did not seem
to play a major role in oncogenic transformation of canine
osteoblasts, while nuclear p53 was confirmed to represent
a negative prognostic marker.
Results
Histological examination
OSAs were classified according to WHO classification
[44], as: 5 productive osteoblastic, 2 non productive
osteoblastic, 1 telengectatic, 2 mixed, 3 fibroblastic, 1
undifferentiated, 1 chondroblastic, and 2 giant cell OSA.
According to the Kirpensteijn’s grading system [45], 4
cases were classified as grade I, 7 as grade II, and 6 as
grade III OSA (Table 1).
β-catenin expression in canine OSA
In normal osteoblasts surrounding bone trabeculae adjacent
to the tumours, β-catenin showed an intense nuclear
expression, and a less intense cytoplasmic-membranous
expression (Figure 1,a). In tumour cells, membranous
β-catenin immunostaining was observed in 65% of the
cases, inconsistent and multifocal (Figure 1,b), observed
in 2/4 grade I, 5/7 grade II and 4/6 grade III cases.
Cytoplasmic staining was found in all the samples
examinated (Figure 1, c). Nuclear localization was
found in only 47% of the cases, observed in 2/4 grade I,
5/7 grade II and 1/6 grade III cases. The number of
positive nuclei were very low: 50% grade I showed no
positive nuclei and 50% a number of positive nuclei
ranging from 0 to 10%; >0 and <10% positive nuclei
were found in 5/7 of grade II; while 5/6 grade III did
not show any positive nuclei (Tables 2 and 3). Most of
the cases showing positive nuclei were fibroblastic OSA
(Figure 1, d) (3 cases) or positive nuclei were found in
spindle shaped cells present in the case of undifferentiated
OSA, and in two cases of productive OSA. Positive nuclei
were not found among giant cells, nor among cells of
neoplastic emboli, where only cytoplasmic immunos-
taining was observed (Figure 2, a).
By Fisher’s exact test moderate/high cytoplasmic β-catenin
expression (≥10% positive cells) in the primary tumours
was predictive of development of metastasis (P = 0.014).
No relations were found between the semi-quantitative
evaluation of β-catenin and the OS by Kaplan-Meier
survival analysis.
Table 1 Patients data
Breed Sex Age
(years)
Localization Histological type Post-surgical
treatment
DFI
(days)
Overall survival
(days)
Development of
metastasis
Grade I
n°1 New Found Land m 11 Left Proximal
humerus
fibroblastic osteosarcoma doxorubicin 1033 1033 No
n°2 Belgian Shepherd
Malinois
m 6 Left distal tibia productive osteoblastic
osteosarcoma
cisplatin/doxorubicin 438 449 Yes
n°3 Great Dane m 5 Left distal tibia fibroblastic osteosarcoma cisplatin/doxorubicin 1250 1250 No
n°4 Mixed m 4 Left distal radius nonproductive osteoblastic
osteosarcoma
cisplatin/doxorubicin 214 1089 Yes
Grade
II
n°5 Great Dane f 4 Right distal radius chondroblastic osteosarcoma cisplatin/doxorubicin 89 168 Yes
n°6 Mixed m 7 Distal ulna mixed osteosarcoma cisplatin/doxorubicin 553 553 No
n°7 Mixed f 8 Left Proximal
humerus
mixed osteosarcoma doxorubicin 503 503 No
n°8 Rottweiler f 7 Right proximal femur poorly differentiated osteosarcoma doxorubicin 623 715 Yes
n°9 German Sheperd m 8 Right proximal
humerus
fibroblastic osteosarcoma cisplatin/doxorubicin 496 496 No
n°10 Maremma Sheepdog m 9 Right distal radius teleangectatic osteosarcoma cisplatin/doxorubicin 261 261 No
n°11 Rottweiler f 7,5 Right distal radius productive osteoblastic
osteosarcoma
cisplatin/doxorubicin 391 391 No
Grade
III
n°12 Boxer f 8 Right distal radius productive osteoblastic
osteosarcoma
cisplatin/doxorubicin 103 169 Yes
n°13 Great Dane m 10 Left distal radius productive osteoblastic
osteosarcoma
cisplatin/doxorubicin 210 242 Yes
n°14 German Sheperd f 7 Left distal femur nonproductive osteoblastic
osteosarcoma
doxorubicin 309 335 Yes
n°15 Rottweiler m 2,5 Distal radius giant cell type osteosarcoma cisplatin 75/167 211 Yes
n°16 New Found Retriever m 7 Left Distal radius productive osteoblastic
osteosarcoma
cisplatin/doxorubicin 126 200 Yes
n°17 Saint Bernard m 7 Left Distal radius giant cell type osteosarcoma cisplatin/doxorubicin 203 203 No
Tumour grade, breed, sex, age, localization, histological type, post-surgical treatment, DFI, overall survival and development of metastasis of the cases included in the present study.
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Figure 1 Immunohistochemical β-catenin expression. a – Osteoblasts lining bone trabeculae surrounding neoplastic tissue. Intense nuclear
immunostaining (arrows) (Bar. 40 μm) b – Non-productive osteoblastic OSA. Multifocal and inconsistent membranous immunostaining (arrows)
(Bar. 80 μm). c - Productive osteoblastic OSA. Diffuse cytoplasmic immunostaining (Bar. 40 μm). d – Fibroblastic OSA. Multifocal nuclear
immunostaining (arrows) (Bar. 80 μm).
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No staining was found in normal osteoblasts surrounding
bone trabeculae adjacent to the tumours, while all samples
investigated showed both nuclear and cytoplasmic sur-
vivin immunostaining. Cytoplasmic survivin expression was
very high (≥75% positive cells) in all the cases evaluated.
Nuclear staining was more intense than cytoplasmic, with
positive mitotic figures observed among all the tumours
(Figure 3, a). Positive nuclei were also multifocally and
inconsistently found in the giant cells. Numerous positive
nuclei were present among cells of neoplastic emboli
(Figure 2, b).
Survivin nuclear expression ranged from 55.55% to
3.86%, with a mean value within the three different
groups of 38.22%± 17.5 (grade I), 16.56%± 7.9 (grade II) and
13.59%± 9 (grade III) (mean value ± standard deviation).
Statistically significant correlation, using Pearson’s cor-
relation coefficient, was observed between nuclear survivin
expression and active caspase 3 expression (ρ = 0.696;Table 2 Immunohistochemical results 1
β-Catenin P53
GRADE N° Nuclear Membranous Cytoplasmic
I 4 2 (50%) 2 (50%) 4 (100%) 2 (50%)
II 7 5 (71%) 5 (71%) 7 (100%) 6 (86%)
III 6 1 (17%) 4 (67%) 6 (100%) 6 (100%)
Positive samples for each molecules investigated grouped in different grades, accorP = 0.008), longer DFI (ρ = 0.741; P = 0.001) and OS
(ρ = 0.748; P = 0.001); the relation between nuclear survivin
expression and active caspase 3 expression seems to be
confirmed by the Kendall’s Taub non parametric test
(τb = 0.513; P = 0.015), while the same test gives less signifi-
cant results with longer DFI (P = 0.177) and OS (P = 0.150).
The Kaplan-Meier analysis and Log-Rank test (P = 0.088)
(Figure 4, a) showed a tendency toward a longer OS in sub-
ject with moderate/high nuclear survivin expression (≥15%
positive cells).
p53 expression in canine OSA
Positive nuclei were observed in 82% of cases, found in
2/4 grade I, 6/7 grade II and 6/6 grade III cases (Tables 2
and 3). Most of giant cells were negative, and scattered posi-
tive nucleoli were also observed (Figure 3, b). Numerous cells
within neoplastic emboli showed positive nuclei (Figure 2, c).
A high nuclear p53 expression (≥25% positive cells)
was significantly associated with a high histologicalProcaspase 3 Active Caspase 3 Survivin
Cytoplasmic Nuclear
4 (100%) 4 (100%) 4 (100%) 4 (100%)
7 (100%) 7 (100%) 7 (100%) 7 (100%)
6 (100%) 6 (100%) 6 (100%) 6 (100%)
ding to Kirpensteijn’s grading system [45].
Table 3 Immunohistochemical results 2
Grade β-catenin p53
N M C
I - - - -
0 2 (50%) 2 (50%) - 2 (50%)
>0 - <10% 2 (50%) 1 (25%) 1 (25%) 2 (50%)
≥10 - <25% - - - -
≥25 - <50% - 1 (25%) 1 (25%) -
≥50% - - 2 (50%) -
II
0 2 (28.6%) 1 (14.3%) - 1 (14.3%)
>0 - <10% 3 (42.8%) 1 (14.3%) 2 (28.6%) 1 (14.3%)
≥10 - <25% 1 (14.3%) 1 (14.3%) 2 (28.6%) 3 (42.8%)
≥25 - <50% 1 (14.3%) 1 (14.3%) 1 (14.3%) 2 (28.6%)
≥50% - 2 (28.6%) 2 (28.6%) -
III
0 5 (83.3%) 2 (33.3%) - -
>0 e <10% - 2 (33.3%) 1 (16.7%) -
≥10 - <25% 1 (16.7%) 1 (16.7%) 2 (33.3%) 1 (16.7%)
≥25 - <50% - 1 (16.7%) 2 (33.3%) 4 (66.6%)
≥50% - - 1 (16.7%) 1 (16.7%)
Number of positive cases (and percentage) for each ranges of positive cells
observed, grouped in different grades, according to Kirpensteijn’s grading
system [45]. N: nuclear; M: membranous; C: cytoplasmic.
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expression (≥10% positive cells) was significantly asso-
ciated with a moderate/high histological grade (II and III)
(P = 0.017) and longer OS (P = 0.004). The Kaplan-Meier
analysis and Log-Rank test (P = 0.049) also showed longer
OS in subject having moderate/high nuclear p53 expres-
sion (≥10% positive cells) (Figure 4, b).
Caspase 3 expression in canine OSA
A diffuse procaspase 3 cytoplasmic immunostaining was
found in all the cases investigated; while multifocal active
caspase 3-positive nuclei were found in all the neoplasticFigure 2 Immunohistochemistry in neoplastic emboli. a – Numerous p
multifocal nuclear (arrows) survivin immunostaining (Bar. 80 μm). c – Weak
immunostaining (Bar. 80 μm).tissues, but none in normal osteoblasts surrounding bone
trabeculae adjacent to the tumours.
Active caspase 3 expression ranged from 65.41% to
5.48%, with a mean value within the three different
groups of 53.82% ± 16.4 (grade I), 30.41% ± 23.4 (grade
II) and 13.78% ± 14.4 (grade III) (mean value ± standard
deviation).
No relations were found between the semi-quantitative
evaluation of procaspase 3 and active caspase 3 and the
investigated clinico-pathological parameters.
Discussion
The present study demonstrated and confirmed the
expression of several important molecules in canine
OSA, showing a potential prognostic value of some of
them, that could also be considered as possible candidates
for a therapeutic target.
Even though the importance of the Wnt/β-catenin
pathway in bone development and homeostasis is well
defined [46,47], the role of β-catenin in the development
and progression of bone tumours is not completely
known [48]. Since OSA formation is probably the result
of an altered bone regulation, it seems likely that deregu-
lation of the Wnt signalling could be associated with
the pathogenesis of OSA. The presence of intense β-
catenin-positive nuclei in normal osteoblasts observed
in the present study would confirm the fundamental
role of the Wnt/β-catenin pathway in the maintenance
of these cells. Indeed, nuclear β-catenin expression has
been considered a hallmark of activation of the Wnt/β-
catenin pathway [26,49] or mutations of β-catenin or
molecules of its degradation complex [50]. Rare or
completely absent positive nuclei were observed in the
most malignant cases examinated herein, even if no signifi-
cant association with the OS was observed, as well as in
neoplastic emboli, suggesting that neither mutations nor
activation of the Wnt/β-catenin pathway would occur in
these cells. In accordance with that, no mutation has been
recently identified in canine β-catenin exon 3, similarly to
human OSA [19], even if a limited number of cases were53-positive nuclei (arrows) (Bar. 160 μm). b – Weak cytoplasmic and
β-catenin cytoplasmic and no nuclear and membranous
Figure 3 Survivin and p53 immunohistochemical expression. a – Productive osteoblastic OSA. Multifocal survivin nuclear immunostaining
(arrows) (Bar. 80 μm). b – Productive osteoblastic OSA. Numerous p53 positive nuclei (arrows) (Bar. 40 μm).
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localization of the protein was detected [51]. Furthermore,
no differences in nuclear β-catenin immunohistochemical
expression were observed in samples obtained from two
populations of canine OSA patients with normal or high
level of serum alkaline phosphatase concentration [52],
known to have negative prognostic value in canine osteo-
sarcoma patients [53]. These results seem to be in agree-
ment with recent investigations in human OSA [26], where
no β-catenin nuclear expression was observed in 90% of
human high grade OSA biopsies examinated and inhibition
of the Wnt/β-catenin pathway has been demonstrated to
be important in osteoblast neoplastic transformation [26].
These observations seemed to confirm the hypothesis that
inactivation of the Wnt/β-catenin pathway could be essen-
tial in OSA progression, differently to what is usually
observed in other cancers [54], opening to new potential
therapeutic strategies. Specific small molecule compounds
that activate Wnt/β-catenin signaling in a highly cell-type
specific manner (human OSA U2OS cell line) have recentlyFigure 4 Kaplan-Meier plots showing influence on survival of survivin
tendency toward a longer survival time (P = 0,088). (b) P53 nuclear express
post-surgical OS (P = 0.049).been identified [55], that could induce the activation of the
Wnt/β-catenin pathway and provide new therapeutic
opportunities. Interestingly, high β-catenin cytoplasmic
expression rate was significantly related to the development
of metastasis. High levels of cytoplasmic protein, in absence
of nuclear staining, could be related to a reduced mem-
branous β-catenin, reported to be associated to invasion
and metastatic potential in human OSA [21], however, an
inhibition of β-catenin nuclear translocation may also be
hypothesized.
Similarly to what has previously been observed in
human [30,31] and canine [36] OSA, both cytoplasmic
and nuclear survivin expression pattern was observed in
canine OSA. Mechanisms controlling survivin nuclear
and/or cytoplasmic localization in tumour cells are often
a debated question, since the item could acquire a different
prognostic significance depending on the tumour type
[56]. Our results seem to be in contrast with a recent study
in which a correlation between survivin immunohisto-
chemical expression and histological grade and mitoticand p53. (a) Nuclear survivin expression score ≥15% showed a
ion score ≥10% appeared to be significantly associated to a longer
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[36]. Similarly, divergent results have been published
concerning the relation between survivin expression and
malignancy of human OSA [30,32-34]. Disagreements
could be related to the presence of several survivin
isoforms, with different, even opposite, functions, and this
might indicate different activities of survivin within the
cell. In particular, two survivin variants potentially act in
an opposite way to the other three variants, with a potential
proapoptotic function: Survivin-2α may attenuate the anti-
apoptotic activity of full length survivin [57], while survivin-
deltaEx3 has been shown to have apoptotic functions [58].
Noteworthy, the polyclonal antibody used in the present
study recognizes all survivin splice variants, and decreased
nuclear survivin expression score was found among more
malignant grade III cases of canine OSA, as well as higher
nuclear survivin expression appeared to be related to a
longer post-treatment OS, similarly to that observed by
Trieb et al. [30] in the human counterpart. A significant
association was revealed between nuclear survivin expres-
sion and the activation of caspase 3, most probably indica-
tive of apoptotic pathway activation, further supporting
the hypothesis that nuclear survivin expression could be
considered a positive prognostic marker in canine OSA.
Indeed, despite a diffuse cytoplasmic staining of its in-
active form (procaspase 3) observed in all the cases exami-
nated, a progressive decreasing of the active caspase 3
mean values was observed in OSA from grade I to III.
Differently to primary tumours, a frequent nuclear
survivin immunostaining was observed among neoplastic
emboli, suggesting a different behaviour of the protein in
OSA metastatic spread. Therefore, further investigations
on survivin expression in metastatic OSA are warranted,
in order to understand its functions and role in the
response to postoperative chemotherapy, since adjuvant
treatment is mainly aimed at controlling the metastatic
disease, and survivin has been frequently associated to
resistance to chemotherapy [59,60]. Recently, this has
been demonstrated also in canine OSA cell lines (Abrams
and D17), where after survivin inhibition an increase of
chemosensitivity to both doxorubicin and carboplatin has
been observed [36]. Survivin has been proposed as a valu-
able target for anticancer therapy [37], and several mole-
cules with a direct or indirect effect on survivin expression
have been identified to date, some of which have been
tested in clinical trials with encouraging results [61].
Decreasing survivin expression through STAT3 [5,62] or
Hsp90 [63] inhibition in canine OSA cell lines has been
recently proposed as a possible new therapeutic approach.
There is a strong evidence of the involvement of p53
mutations in the development of canine OSA [41,64,65],
as well as in the human counterpart [66,67]. In the
present study, highest levels of expression of nuclear p53
were significantly associated with a shorter post surgicalOS, and appeared to be related to the development of
metastasis, confirming the importance of p53 as a nega-
tive prognostic marker in canine OSA, in accordance
to previous published data regarding canine OSA, sug-
gesting that, similarly to human OSA [68,69], altera-
tions in p53 functions are associated with highly
aggressive tumour behaviour [70,71]. Deregulation of
the p53-survivin subsystem has been proposed to play
an important role in several tumour types [72], since,
WTp53 is able to repress survivin expression at both
the mRNA and protein level [40]. In spite of this, our
results suggests that different mechanisms could regulate
survivin expression in canine OSA.
Conclusions
Data obtained from the present immunohistochemical
study suggest survivin as a potential positive prognostic
marker, rather than a marker of poor prognosis, even if
its presence in metastatic emboli suggests its possible
involvement in the malignant progression of canine
OSA. Further investigations, in particular on the expres-
sion and roles of its different isoforms, should be per-
formed in order to clarify if survivin could represent a
valid biomarker in this kind of tumour.
Lastly, the present data suggest that β-catenin, a key
molecule for normal osteoblast differentiation, could not
play a key role in the neoplastic transformation of canine
osteoblasts, as recently suggested in human OSA. Further
studies should be done in order to confirm this hypothesis.
Methods
Tissue Samples and Clinical data
This retrospective study looked at of 17 canine OSA
surgical samples, provided by the Department of Animal
Pathology, Faculty of Veterinary Medicine, University of
Torino (Italy), for which survival data were also pro-
vided. All the dogs included in the present study had an
appendicular OSA (histologically confirmed) at presenta-
tion and no evidence of metastasis. Clinical staging
included history, physical exam, complete blood count,
serum biochemical profile, urinalysis and abdominal ultra-
sound. Limb (latero-lateral [LL] and antero-posterior [AP]
views) and chest (right and left LL, and dorso-ventral
[DV] views) radiographic evaluation was performed to
examine features and extension of the tumour and
presence of lung metastasis, respectively. Computed
Tomography was performed in case of radiographic
suspicion of lung metastasis. Regional lymph nodes were
aspirated and cytologically examined when enlarged at
clinical palpation. Initial diagnosis of the tumour was
attempted by fine needle aspiration and cytology but, for a
more specific identification of the tumour type, a pre-
operative biopsy was obtained in all cases using a Jamshidi
needle and submitted to histopathology. Histopathology
Table 4 Primary antibodies used in immunohistochemical analysis
MOLECULE TYPE OF Ab COMPANY WORKING DILUTION POSITIVE CONTROL
β-catenin Rabbit PAb Santa Cruz Biotecnology 1:250 Normal canine skin [80]
Survivin Rabbit PAb NOVUS Biologicals 0.7 μg/ml Canine cutaneous SCC [79]
p53 Rabbit PAb NovoCastra 1:400 Canine nail bed SCC (Figure 5)
Procaspase 3 Rat MAb NovoCastra 1:85 Normal canine tonsil [81]
Active Caspase 3 Mouse MAb Oncogene 1:200 Canine breast carcinoma [81]
Clonality, company, working dilutions and positive controls used for each antibody. PAb: polyclonal antibody; MAb: monoclonal antibody. SCC: squamous cell
carcinoma.
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case of limb amputation or limb sparing using an allograft
to substitute the tumour segment) or on a sample of the
tumour (in case of limb sparing using the pasteurized neo-
plastic autograft), in order to confirm the diagnosis
[73,74]. All dogs included in the present study were surgi-
cally treated (amputation or limb sparing) before receiving
adjuvant chemotherapy using doxorubicin (30 mg/m2, 4–5
administrations, 21 days apart) or cisplatin (70 mg/m2,
4–5 administrations, 21 days apart) as a single agent, or
a combination of cisplatin and doxorubicin (4 cycles,
21 days apart, each cycle consisting of cisplatin 50 mg/m2
at day 1 and doxorubicin 15 mg/m2 at day 2). One of the
three chemotherapy protocols was chosen based on the
dog clinical status and owners compliance, since no proto-
col has been demonstrated to be superior [75-78]. Besides,
histopathological tumour grade never influenced the
choice of the chemotherapeutic protocol adopted. Canine
patients were clinically and radiographically examined
every 3 months during the first year after the conclusion
of chemotherapy and then every 6 months for a minimum
of 2 years. DFI (disease free interval) was considered as
the period in days from surgery to recurrence and/or
metastasis development, while OS (overall survival) as the
period in days from surgery to death for tumour-related
causes; for dogs still alive at the time of writing, OS wasFigure 5 Positive control tissues for p53. a- Human mammary carcinom
squamous cell carcinoma. Numerous p53-positive nuclei (arrows) (Bar. 40 μthe number of days from surgery to the last clinical
examination (patients’ data are summarized in Table 1).
Histological examination
All specimens were routinely fixed in 10% formalin,
embedded in paraffin wax, and 4–5 μm-thick sections
were examined using haematoxylin and eosin (H&E)
staining and visualized by light microscopy. Tumours
were histologically classified according to the World
Health Organization (WHO) criteria [44], and histo-
logical grade was determined according to the system
proposed by Kirpensteijn et al. [45].
Immunohistochemical Examination
Dewaxed and rehydrated tissue sections were immunos-
tained by the streptavidin-biotin peroxidase complex
(SAB) method, using specific primary antibodies (Abs)
reported in Table 4, incubated overnight in a humidified
chamber at 4°C. Immunohistochemical analysis followed
procedure as reported in previous studies [79]. Endogen-
ous peroxidase was blocked with H2O2 3% in absolute
methanol for 45 min. Antigen retrieval was undertaken
by heat-treating sections in citrate buffer at pH 6
(β-catenin, caspase 3) or Tris-EDTA pH 9.0 (p53) in a
microwave oven for 5min. (3 cycles) or in citrate buffer
at pH 6 in a pressure cooker for 20 min. (survivin).a. p53-positive nuclei (arrows) (Bar. 40 μm). b – Canine nail bed
m).
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diaminobenzidine (DAB, D5905, Sigma-Aldrich, St. Louis,
MO, USA) solution, which was applied for 5 min, followed
by a light counterstain with Mayer’s haematoxylin (Merck,
Darmstadt, Germany) for 1 min. Positive control slides
were used for each Abs using a tissue of known pattern of
expression of each molecules (Table 4). Anti-p53 antibody
validation was performed using samples of human mam-
mary carcinoma (Figure 5, a) and a samples of canine nail
bed squamous cell carcinoma (SCC) (Figure 5, b) then
used as positive control. A negative control was performed
in all instances by omitting the primary antibody and
incubating tissue sections with Tris Buffered Saline (TBS);
for active caspase 3, an irrelevant antibody directed against
an unrelated antigen (mouse anti human desmin monoclonal
antibody – Dako, Glostrub, Denmark) was also used.
Quantification of Immunostaining and Statistical Analysis
Neoplastic tissues were scored by two pathologists as
follow.
Survivin and caspase 3 expression was evaluated by
counting the number of positive nuclei in 10 HPF at
400X, counting approximately 1000 cells, and expressed
as a percentage. Cytoplasmic survivin expression was
diffusely present in 100% of the cases evaluated.
For p53 only nuclear staining was considered as positive,
since nuclear immunostaining is suggestive of its mutation
[68]; β-catenin expression was classified as membranous
(localised at cell-cell boundaries), cytoplasmic (uniformly
distributed throughout the cytoplasm) and nuclear. A
semi-quantitative immunohistochemical assessment was
performed and samples were subdivided based on the
protein expression levels in 4 ranges for β-catenin and
p53 (absent: no positive cells; low: >0% - <10% positive
cells; moderate: ≥10% - <50% positive cells; high: ≥50%
positive cells) and 5 ranges for procaspase 3 and survivin
(absent: no positive cells; low: >0% - <10% positive cells;
moderate: ≥10% - <50% positive cells; high: ≥50% - <75%
positive cells; very high ≥75% positive cells).
Fisher's exact test was applied to evaluate the associ-
ation between the expression levels of the investigated
molecules and clinico-pathological parameters. Pearson
correlation test and Kendall’s Taub test were applied to
examine the relations between the expression levels
of nuclear survivin and p53, DFI, OS. Kaplan Meier
analysis was used to estimate survival, and the significances
of the differences were determined by the Log-Rank test.
For this purpose, the cases were grouped according to the
expression score as follows: <10% positive cells (absent +
low semiquantitative evaluation) versus ≥10% positive
cells (moderate + high semiquantitative evaluation) for
p53 and β-catenin; <15% positive cells (absent + low semi-
quantitative evaluation) versus ≥15% positive cells (mod-
erate + high semiquantitative evaluation) for survivin; or<25% positive cells (absent/low +moderate semiquantita-
tive evaluation) versus ≥25% positive cells (high semiquan-
titative evaluation). Analyses were performed using the
IBM SPSS19 statistical software, and the conventional 5%
level was used to define statistical significance.Authors’ contributions
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